ImmunoGen's lead armed antibody — mirvetuximab soravtansine — has failed a late-stage study as a monotherapy in third line platinum-resistant ovarian cancer patients, a miss that could derail studies testing the drug as part of a combo.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.Free Subscription